The Study
Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice.
This study watched what happened to a few sick mice after giving them special sugar-regulating chemicals. It saw that one chemical made their blood sugar a little better, but it didn't prove the chemical caused it — maybe the mice just happened to feel better that week. We can't say it would work in people.
Analysis score
Maximum 72 for a cohort study.
Where the score came from
Scientists gave mice with diabetes a broken version of a hormone called GIP to see if it still helped control blood sugar.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 516 / 100
Quality score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Key takeaways
Summary
Based on the study abstract and findings.
- 1The improvement was small but real — like lowering blood sugar by a few points — and only happened while the treatment continued.
- 2Mice given the broken GIP (GIP(3-42)) had slightly lower blood sugar after meals and better insulin sensitivity, but their insulin levels didn't change.
- 3The other broken hormone (GLP-1(9-36)amide) did nothing.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
The Journal of endocrinology
Year
2006
Authors
JC Parker, Kerry S. Lavery, N. Irwin, Brian D. Green, B. Greer, P. Harriott, F. O’Harte, V. Gault, P. Flatt
Related Content
Claims (4)
In obese diabetic mice, daily injections of GIP(3-42) for 14 days lowered blood glucose levels, improved how the body responds to glucose, and increased insulin sensitivity, without changing insulin production, body weight, food intake, or pancreatic islet structure.
In obese diabetic mice, daily injections of GIP(3-42) or GLP-1(9-36)amide for 14 days did not alter the amount of insulin in the pancreas, the number of islets, or their structure.
In obese diabetic mice, daily injections of GIP(3-42) for 14 days increased insulin sensitivity without altering insulin levels in the blood, showing that the effect occurs through mechanisms outside the pancreas.
In obese diabetic mice, a daily injection of GLP-1(9-36)amide at 25 nmol/kg for 14 days did not change fasting or after-meal blood sugar levels, glucose processing, insulin function, body weight, food intake, or pancreatic islet structure.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.